A Prospective, Multicenter, Non-interventional, Real-world Study to Characterize Changes in Molecular Markers After Three Weeks of Targeted Therapy With Oxitinib in EGFRm NSCLC

Comprehensive Analysis of Gene Mutation Profile in Chinese NSCLC Patients by Next-generation Sequencing

NCT03609918 ·Status: COMPLETED

Almonertinib With Chemotherapy in mEGFR NSCLC

NCT04646824 ·Status: UNKNOWN ·Phase: PHASE2

Intercalating and Maintenance Gefitinib in Combination With Chemotherapy for Advanced EGFR-mutant NSCLC

NCT02299765 ·Status: TERMINATED ·Phase: PHASE4

Aumolertinib Versus Osimertinib As First-line Therapy for Patients with EGFR Mutated Locally Advanced or Metastatic Non-small-cell Lung Cancer

NCT06752408 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

Evaluate EGFR Mutation Status and Impact Factors in North China

NCT02620657 ·Status: COMPLETED

Exploring Cancer Evolution, Prognostic and Predictive Biomarkers in EGFR-mutant NSCLC

NCT05997719 ·Status: RECRUITING

Clinical Trial of Neoadjuvant Targeted Treatment to NSCLC Patients

NCT03203590 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3

A Study to Predict Gefitinib' s Efficacy for Lung Cancer by Plasma Free Nucleic Acids EGFR Gene Mutation Test

NCT02738684 ·Status: UNKNOWN

Gefitinib and Berberine in the First-line Treatment of Lung Adenocarcinoma With EGFR Mutation

NCT03486496 ·Status: UNKNOWN ·Phase: PHASE2

Study on Potential Biomarkers Associated With Clinical Phenotype of EGFR-TKIs in No-small Cell Lung Cancer in China

NCT02381808 ·Status: UNKNOWN

Phase II Study of Afatinib Plus Bevacizumab in the Treatment Epidermal Growth Factor Receptor (EGFR) Exon G719X, S768I, and L861Q Mutation Metastatic Non-Small Cell Lung Cancer

NCT05267288 ·Status: UNKNOWN ·Phase: PHASE2

Efficacy of Platinum-based Chemotherapy Plus Immune Checkpoint Inhibitors for EGFR/ALK/ROS1 Mutant Lung Cancer

NCT05284539 ·Status: RECRUITING ·Phase: PHASE2

Gefitinib 500mg Versus 250mg in Patients With NSCLC With Stable Disease After a Month Treatment of Gefitinib 250mg

NCT01017679 ·Status: COMPLETED ·Phase: PHASE2

Efficacy and Safety of Platinum-based Chemotherapy + Bevacizumab + Durvalumab, and Salvage SBRT for IV Non-Small Cell Lung Cancer Patients With EGFR Mutations After Failure of First Line Osimertinib: A Multicenter, Prospective, Phase II Clinical Study

NCT04517526 ·Status: UNKNOWN ·Phase: PHASE2

Neoadjuvant Almonertinib Followed by Chemo-immunotherapy in II-IIIB EGFR-mutant NSCLC

NCT06300424 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Neoadjuvant Immunotherapy in EGFR-mutant Localized NSCLC

NCT05244213 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

A Study of BL-B01D1 and Almonertinib in Patients With Resectable EGFR+ Stage II-IIIB NSCLC

NCT06951464 ·Status: RECRUITING ·Phase: PHASE2

Assessing an Oral EGFR Inhibitor,YK-209A in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR

NCT05767866 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2

Neoadjuvant Befotertinib Combined Bevacizumab or Platinum-based Double Chemotherapy for Resectable Locally-advanced EGFR Mutation-positive Non-Small Cell Lung Cancer

NCT06755684 ·Status: RECRUITING ·Phase: PHASE2

Efficacy and Safety of Almonertinib Combined With or Without Chemotherapy as an Adjuvant Treatment for Stage II-IIIA Non-small Cell Lung Carcinoma Following Complete Tumour Resection

NCT04762459 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE3

High-Dose,Pulsatile Erlotinib/Gefitinib for Advanced NSCLC Patients After Failure of Standard Dose EGFR-TKIs

NCT01965275 ·Status: UNKNOWN ·Phase: PHASE2

Gefitinib Combined With Chemotherapy or Antiangiogensis in Patients With Bim Deletion or Low EGFR Mutation Abundance

NCT02930954 ·Status: UNKNOWN ·Phase: PHASE2

Evaluation System for the Efficacy of Immunologic Checkpoint Inhibitors in NSCLC

NCT04629027 ·Status: UNKNOWN

Gefitinib Long-term Survivor Study

NCT02932345 ·Status: TERMINATED

Study to Assess the Efficacy and Safety of Adjuvant Osimertinib in NSCLC With Uncommon EGFRm

NCT05546866 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2